New paradigms in drug R&D: A personal perspective

Authors

  • David C U'Prichard Druid Consulting LLC

DOI:

https://doi.org/10.5912/jcb502

Keywords:

pharma R&D, venture capital, new R&D models, globalization, virtualization

Abstract

The Author discusses the recent productivity problems in the pharmaceutical industry, in the context of his 30 year career, and the current responses of the industry driven strongly by disaggregation of the historic R&D model, new fluidites of capital access, and the impacts of genomics and globalization.

Author Biography

David C U'Prichard, Druid Consulting LLC

is currently venture investor and director of 6 biotechnology companies. Formerly CEO, 3-Dimensional Pharmaceuticals, Chairman R&D Smithkline Beecham, EVP and Global Director of Research, Zeneca.

Downloads

Additional Files

Published

2012-04-01

Issue

Vol. 18 No. 2 (2012)

Section

Commentary